| Mrs Heather Mae Curley Hankins, | |
|
10021 7 Mile Rd, Caledonia, WI 53108-9677 | |
| (414) 852-0826 | |
| Not Available |
| Full Name | Mrs Heather Mae Curley Hankins |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 10021 7 Mile Rd, Caledonia, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396295838 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 320275 - 31 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Heather Mae Curley Hankins, 10021 7 Mile Rd, Caledonia, WI 53108-9677 Ph: (414) 852-0826 | Mrs Heather Mae Curley Hankins, 10021 7 Mile Rd, Caledonia, WI 53108-9677 Ph: (414) 852-0826 |
News Archive
People with multiple sclerosis (MS) who have relapses within the first five years of onset appear to have more severe disability in the short term compared to people who do not have an early relapse, according to a new study published in the November 4, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology. The study is one of the first to examine how MS relapses affect people during different time periods of the disease.
Medicines for Malaria Venture has developed a framework to evaluate the risk of resistance for the antimalarial compounds in its portfolio. A paper based on this work: A framework for assessing the risk of resistance for antimalarials in development has been published in the Malaria Journal today.
Brazilian textile companies have begun producing and marketing fabrics treated with silver and silica nanoparticles developed by the research groups at the Centre for Functional Materials (CDMF) and the Theoretical and Computational Chemistry Laboratory (QTC) at the Universitat Jaume I, in collaboration with the company Nanox Tecnologia, which provide the new fabrics with antibacterial, antifungal and antiviral properties with 99.99% effectiveness.
Johns Hopkins researchers report successful use of heart imaging to predict the benefit or futility of catheter ablation, an increasingly popular way to treat atrial fibrillation, a common heart rhythm disorder.
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has started its phase II clinical study of a vaccine for primary prevention of Clostridium difficile infection (CDI). The trial starting in the United States is focused on evaluating prevention of the first episode of CDI in at-risk individuals, which includes adults with imminent hospitalization or current or impending residence in a long-term care or rehabilitation facility.
› Verified 4 days ago
Mrs. Nancy Ann Schmidt, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 3842 Hwy G, Caledonia, WI 53108 Phone: 262-880-7011 |